Boston Scientific Corp.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $20.07B | $16.75B | $14.24B | $12.68B | $11.89B | $9.91B | $10.74B |
| Endoscopy | — | $2.92B | $2.69B | $2.48B | $2.22B | $2.14B | $1.78B | $1.89B |
| Urology | — | $2.71B | $2.20B | $1.96B | $1.77B | $1.58B | $1.29B | $1.41B |
| Neuromodulation | — | $1.20B | $1.11B | $976.0M | $917.0M | $909.0M | $761.0M | $873.0M |
| Cardiac Rhythm Management | — | $2.33B | $2.28B | $2.22B | $2.10B | $2.02B | $1.70B | $1.94B |
| Electrophysiology | — | $3.33B | $1.90B | $800.0M | $585.0M | $365.0M | $287.0M | $329.0M |
| Interventional Cardiology | — | — | $2.65B | $2.42B | $2.23B | $3.04B | $2.30B | $2.82B |
| Peripheral Interventions | — | — | $2.41B | $2.11B | $1.90B | $1.82B | $1.58B | $1.39B |
| Watchman | — | $1.96B | $1.52B | $1.27B | $1.02B | — | — | — |
| Interventional Cardiology & Vascular Therapies | — | $4.64B | — | — | — | — | — | — |
| Interventional Oncology & Embolization | — | $996.0M | — | — | — | — | — | — |
| Specialty Pharmaceuticals/Other | — | — | $0 | $0 | $-60.0M | $13.0M | $219.0M | $81.0M |
| Cost of Revenue | — | $6.22B | $5.26B | $4.35B | $3.96B | $3.71B | $3.47B | $3.12B |
| Gross Profit | — | $13.85B | $11.49B | $9.90B | $8.73B | $8.18B | $6.45B | $7.62B |
| Gross Margin | — | 69.0% | 68.6% | 69.5% | 68.8% | 68.8% | 65.0% | 71.0% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | $6.89B | $5.98B | $5.19B | $4.52B | $4.36B | $3.79B | $3.94B |
| Operating Income | — | $3.61B | $2.60B | $2.34B | $1.65B | $1.20B | $-80.0M | $1.52B |
| Operating Margin | — | 18.0% | 15.5% | 16.5% | 13.0% | 10.1% | -0.8% | 14.1% |
| Interest Expense | — | $349.0M | $305.0M | $265.0M | $470.0M | $341.0M | $361.0M | $473.0M |
| Pretax Income | — | $3.39B | $2.28B | $1.99B | $1.14B | $1.08B | $-79.0M | $687.0M |
| Income Tax Expense | — | $493.0M | $436.0M | $393.0M | $443.0M | $36.0M | $2.0M | $-4.01B |
| Net Income | — | $2.89B | $1.85B | $1.59B | $698.0M | $1.04B | $-82.0M | $4.70B |
| Net Margin | — | 14.4% | 11.0% | 11.2% | 5.5% | 8.8% | -0.8% | 43.8% |
| EPS (Basic) | — | $1.96 | $1.26 | $1.08 | $0.45 | $0.69 | $-0.08 | $3.38 |
| EPS (Diluted) | — | $1.94 | $1.25 | $1.07 | $0.45 | $0.69 | $-0.08 | $3.33 |
| Shares Outstanding (Basic) | 1.48B | 1.48B | 1.47B | 1.45B | 1.43B | 1.42B | 1.42B | 1.39B |
| Shares Outstanding (Diluted) | 1.48B | 1.49B | 1.49B | 1.46B | 1.44B | 1.43B | 1.42B | 1.41B |
| Dividends Per Share | — | — | — | — | — | — | — | — |